Last 12 months
Inside the activity.
18 purchase rows · 9 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 7 | 0 |
| Feb 2026 | 3 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 4 |
| May 2026 | 5 | 1 |
| Jun 2026 | 2 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2022 Filed Aug 17, 2022 11:00 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 3,000 | $0.91 | $2,730.00 |
DisclosureSEC source: 0001185185-22-000961 · ownership.xml · nonDerivative · entry 2 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,718,788 Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 11:00 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 3,000 | $0.92 | $2,766.00 |
DisclosureSEC source: 0001185185-22-000961 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,715,788 Read SEC document |
| May 25, 2022 Filed May 26, 2022 11:15 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 9,300 | $1.15 | $10,695.00 |
DisclosureSEC source: 0001185185-22-000699 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,712,788 Read SEC document |
| May 24, 2022 Filed May 25, 2022 08:30 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 8,744 | $1.10 | $9,600.91 |
DisclosureSEC source: 0001185185-22-000692 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,703,488 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.05 to $1.15, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| May 23, 2022 Filed May 24, 2022 13:51 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 11,850 | $1.14 | $13,538.63 |
DisclosureSEC source: 0001185185-22-000688 · ownership.xml · nonDerivative · entry 2 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,694,744 F1 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.14 to $1.15, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| May 20, 2022 Filed May 24, 2022 13:51 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 3,650 | $1.13 | $4,124.50 |
DisclosureSEC source: 0001185185-22-000688 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,682,894 Read SEC document |
| May 12, 2022 Filed Jun 21, 2022 17:01 UTC |
Hrkac FrederickDirector
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001185185-22-000764 · ownership.xml · derivative · entry 1 Hrkac Frederick · CIK 0001933130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-12 F1 · derivative.exercise_date: 50% of the shares underlying this stock option vested and became exercisable immediately on the date of grant and 50% will vest and become exercisable on the first anniversary of the date of the director appointment on April 28, 2022, provided Mr. Hrkac is still serving as a director on such date and subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan. Read SEC document |
| May 02, 2022 Filed May 4, 2022 18:03 UTC |
Klein James LDirector
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-22-000563 · ownership.xml · derivative · entry 1 Klein James L · CIK 0001523842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-02 F1 · derivative.exercise_price: The options will have an exercise price equal to the arithmetic mean of the sale prices of the Company's common stock (or the closing bids, if no sales are reported), for the ten trading days immediately following the date of the grant. F2 · derivative.exercise_date: 50% of the shares underlying this stock option vested and became exercisable immediately on the date of grant and 50% will vest and become exercisable on the first anniversary of the date of the director appointment on May 2, 2022, provided Mr. Klein is still serving as a director on such date and subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan. Read SEC document |
| March 30, 2022 Filed Apr 8, 2022 18:22 UTC |
Sieckhaus JohnChief Operating Officer
|
GrantOptions · Derivative | 350,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001185185-22-000415 · ownership.xml · derivative · entry 2 Sieckhaus John · CIK 0001921290 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-03-30 F2 · derivative.exercise_date: The shares underlying this stock option will vest over three years, with 1/3 vesting on the first anniversary of March 30, 2022 and 2/3 vesting in substantially equal quarterly installments thereafter, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan. Read SEC document |
| March 30, 2022 Filed Apr 8, 2022 18:25 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
GrantRestricted Stock · Derivative | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-22-000419 · ownership.xml · derivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires not disclosed F1 · derivative.exercise_price: The shares of restricted stock shall be fully vested as of March 30, 2022, the date of the grant. F1 · derivative.exercise_date: The shares of restricted stock shall be fully vested as of March 30, 2022, the date of the grant. F1 · derivative.expiration_date: The shares of restricted stock shall be fully vested as of March 30, 2022, the date of the grant. Read SEC document |
| March 30, 2022 Filed Apr 8, 2022 18:24 UTC |
CHAUSSY STEVEChief Financial Officer
|
GrantRestricted Stock · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-22-000417 · ownership.xml · derivative · entry 1 CHAUSSY STEVE · CIK 0001261041 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_price: The shares of restricted stock shall be fully vested as of March 30, 2022, the date of the grant. F1 · derivative.exercise_date: The shares of restricted stock shall be fully vested as of March 30, 2022, the date of the grant. F1 · derivative.expiration_date: The shares of restricted stock shall be fully vested as of March 30, 2022, the date of the grant. Read SEC document |
| March 21, 2022 Filed Apr 8, 2022 18:22 UTC |
Sieckhaus JohnChief Operating Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-22-000415 · ownership.xml · nonDerivative · entry 1 Sieckhaus John · CIK 0001921290 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: The reporting person received the shares as a one-time signing bonus upon the commencement of the reporting person's employment with the Company. Read SEC document |
| December 28, 2021 Filed Jan 3, 2022 16:00 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-22-000002 · ownership.xml · nonDerivative · entry 2 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,679,244 Read SEC document |
| December 28, 2021 Filed Jan 3, 2022 16:00 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-22-000002 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,699,244 Read SEC document |
| December 28, 2021 Filed Apr 25, 2022 17:07 UTC |
FOLEY DONALD EDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001185185-22-000489 · ownership.xml · derivative · entry 1 FOLEY DONALD E · CIK 0001014326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. Read SEC document |
| December 28, 2021 Filed Apr 25, 2022 17:16 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001185185-22-000493 · ownership.xml · derivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. Read SEC document |
| December 28, 2021 Filed Apr 25, 2022 17:18 UTC |
NAVARRO SAMUEL EDirector
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001185185-22-000495 · ownership.xml · derivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. Read SEC document |
| December 28, 2021 Filed Apr 25, 2022 21:22 UTC |
Zook Anthony P.Director
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001185185-22-000499 · ownership.xml · derivative · entry 1 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. Read SEC document |
| December 28, 2021 Filed Apr 25, 2022 21:20 UTC |
Weild IV DavidDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001185185-22-000497 · ownership.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. Read SEC document |
| December 28, 2021 Filed Apr 25, 2022 21:05 UTC |
Barry James JDirector
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001185185-22-000487 · ownership.xml · derivative · entry 1 Barry James J · CIK 0001541253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. Read SEC document |
| December 28, 2021 Filed Apr 25, 2022 21:15 UTC |
Gallagher Patrick JosephDirector
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001185185-22-000491 · ownership.xml · derivative · entry 1 Gallagher Patrick Joseph · CIK 0001648003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:05 UTC |
Barry James JDirector
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001185185-21-001449 · ownership.xml · derivative · entry 1 Barry James J · CIK 0001541253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-10-04 F1 · derivative.exercise_date: 50% of the shares underlying this stock option vested and became exercisable immediately on the date of grant and 50% will vest and become exercisable on the first anniversary of the date of the director appointment on September 20, 2022, provided Dr. Barry is still serving as a director on such date and subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan. Read SEC document |
| September 21, 2021 Filed Sep 29, 2021 13:56 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 5,950 | $2.85 | $16,957.50 |
DisclosureSEC source: 0001185185-21-001398 · ownership.xml · nonDerivative · entry 2 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,719,244 Read SEC document |
| September 20, 2021 Filed Sep 29, 2021 13:56 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 2,636 | $2.81 | $7,407.16 |
DisclosureSEC source: 0001185185-21-001398 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,713,294 Read SEC document |
| September 02, 2021 Filed Sep 2, 2021 12:56 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 1,200 | $3.09 | $3,713.04 |
DisclosureSEC source: 0001185185-21-001233 · ownership.xml · nonDerivative · entry 2 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,710,658 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.07 to $3.22, inclusive. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 12:48 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 6,400 | $3.09 | $19,802.24 |
DisclosureSEC source: 0001185185-21-001229 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,705,058 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.08 to $3.11, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 12:56 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 4,400 | $3.10 | $13,624.16 |
DisclosureSEC source: 0001185185-21-001233 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,709,458 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.09 to $3.097, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 10:00 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer
|
PurchaseCommon Stock | 9,000 | $3.02 | $27,194.40 |
DisclosureSEC source: 0001185185-21-001222 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,698,658 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.02 to $3.034, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| August 13, 2021 Filed Aug 13, 2021 11:55 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 11,700 | $3.18 | $37,206.00 |
DisclosureSEC source: 0001185185-21-001117 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,689,658 Read SEC document |
| August 13, 2021 Filed Sep 3, 2021 16:58 UTC Amendment |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 11,700 | $3.18 | $37,206.00 |
DisclosureSEC source: 0001185185-21-001253 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,689,658 F1 · kind: The purpose of this Amendment is to correct the Transaction Code in column 3 of Table I, which inadvertently used Transaction Code "A" instead of "P". Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 09:52 UTC |
NAVARRO SAMUEL EDirector
|
Exercise / conversionRestricted Stock Units ("RSUs") · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-21-000847 · ownership.xml · derivative · entry 2 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents the right to receive, at settlement, one (1) share of common stock. F2 · derivative.exercise_date: On June 21, 2019, the reporting person was granted 50,000 RSUs, with 50% to vest on June 21, 2020 and the remaining 50% to vest on June 21, 2021, subject to reporting person's continued service through each vest date. F2 · derivative.expiration_date: On June 21, 2019, the reporting person was granted 50,000 RSUs, with 50% to vest on June 21, 2020 and the remaining 50% to vest on June 21, 2021, subject to reporting person's continued service through each vest date. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 09:52 UTC |
NAVARRO SAMUEL EDirector
|
Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001185185-21-000847 · ownership.xml · nonDerivative · entry 1 NAVARRO SAMUEL E · CIK 0001269368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents the right to receive, at settlement, one (1) share of common stock. Read SEC document |
| June 10, 2021 Filed Jun 10, 2021 14:31 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 4,000 | $4.03 | $16,110.00 |
DisclosureSEC source: 0001185185-21-000791 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,677,958 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.01 to $4.05, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 10, 2021 Filed Sep 3, 2021 16:56 UTC Amendment |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 4,000 | $4.03 | $16,110.00 |
DisclosureSEC source: 0001185185-21-001251 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,677,958 F1 · kind: The purpose of this Amendment is to correct the Transaction Code in column 3 of Table I, which inadvertently used Transaction Code "A" instead of "P". Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 10:21 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 2,000 | $3.57 | $7,130.00 |
DisclosureSEC source: 0001185185-21-000778 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,673,958 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.55 to $3.58, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 07, 2021 Filed Sep 3, 2021 16:55 UTC Amendment |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 2,000 | $3.57 | $7,130.00 |
DisclosureSEC source: 0001185185-21-001249 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,673,958 F1 · kind: The purpose of this Amendment is to correct the Transaction Code in column 3 of Table I, which inadvertently used Transaction Code "A" instead of "P". Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 12:30 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 3,000 | $3.67 | $11,010.00 |
DisclosureSEC source: 0001185185-21-000774 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671,958 Read SEC document |
| June 03, 2021 Filed Sep 3, 2021 16:54 UTC Amendment |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 3,000 | $3.67 | $11,010.00 |
DisclosureSEC source: 0001185185-21-001247 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671,958 F1 · kind: The purpose of this Amendment is to correct the Transaction Code in column 3 of Table I, which inadvertently used Transaction Code "A" instead of "P". Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 13:55 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 4,000 | $3.91 | $15,630.00 |
DisclosureSEC source: 0001185185-21-000756 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,668,958 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.88 to $3.93, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 02, 2021 Filed Sep 3, 2021 16:53 UTC Amendment |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 4,000 | $3.91 | $15,630.00 |
DisclosureSEC source: 0001185185-21-001245 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,668,958 F1 · kind: The purpose of this Amendment is to correct the Transaction Code in column 3 of Table I, which inadvertently used Transaction Code "A" instead of "P". Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 11:57 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 3,000 | $3.70 | $11,090.10 |
DisclosureSEC source: 0001185185-21-000748 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,664,958 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.65 to $3.71, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| May 28, 2021 Filed Sep 3, 2021 16:51 UTC Amendment |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 3,000 | $3.70 | $11,090.10 |
DisclosureSEC source: 0001185185-21-001243 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,664,958 F1 · kind: The purpose of this Amendment is to correct the Transaction Code in column 3 of Table I, which inadvertently used Transaction Code "A" instead of "P". Read SEC document |
| May 27, 2021 Filed May 28, 2021 09:30 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 4,200 | $3.52 | $14,790.72 |
DisclosureSEC source: 0001185185-21-000741 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661,958 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.48 to $3.62, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| May 27, 2021 Filed Sep 3, 2021 16:50 UTC Amendment |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 4,200 | $3.52 | $14,790.72 |
DisclosureSEC source: 0001185185-21-001241 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661,958 F1 · kind: The purpose of this Amendment is to correct the Transaction Code in column 3 of Table I, which inadvertently used Transaction Code "A" instead of "P". Read SEC document |
| May 26, 2021 Filed May 26, 2021 13:02 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 4,000 | $3.28 | $13,128.40 |
DisclosureSEC source: 0001185185-21-000726 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,654,558 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.30, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| May 26, 2021 Filed May 27, 2021 09:31 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 3,200 | $3.43 | $10,966.08 |
DisclosureSEC source: 0001185185-21-000735 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,657,758 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.33 to $3.49, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| May 26, 2021 Filed May 27, 2021 09:30 UTC Amendment |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 4,000 | $3.28 | $13,128.40 |
DisclosureSEC source: 0001185185-21-000734 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,654,558 F2 · security: This transaction is not new or revised, but is being reported again solely to gain access to the EDGAR filing system. This Amendment is Amendment Number 1 to the Form 4 originally filed on May 26, 2021. The purpose of this Amendment is to correct footnote 1 to the Form 4, which stated that the shares in this transaction were sold by Mr. Londoner. F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.27 to $3.30, inclusive. The reporting person undertakes to provide to BioSig Technologies, Inc., any security holder of BioSig Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| May 26, 2021 Filed Sep 3, 2021 16:49 UTC Amendment |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 3,200 | $3.43 | $10,966.08 |
DisclosureSEC source: 0001185185-21-001239 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,657,758 F1 · kind: The purpose of this Amendment is to correct the Transaction Code in column 3 of Table I, which inadvertently used Transaction Code "A" instead of "P". Read SEC document |
| May 26, 2021 Filed Sep 3, 2021 16:47 UTC Amendment |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 4,000 | $3.28 | $13,128.40 |
DisclosureSEC source: 0001185185-21-001237 · ownership.xml · nonDerivative · entry 1 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,654,558 F1 · kind: The purpose of this Amendment is to correct the Transaction Code in column 3 of Table I, which inadvertently used Transaction Code "A" instead of "P". Read SEC document |
| May 25, 2021 Filed May 26, 2021 09:30 UTC |
LONDONER KENNETH LDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock | 1,000 | $3.23 | $3,230.00 |
DisclosureSEC source: 0001185185-21-000723 · ownership.xml · nonDerivative · entry 5 LONDONER KENNETH L · CIK 0001449534 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650,558 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.